ABSTRACT
INTRODUCTION: Ventilatory ratio (VR) is a simple bedside index of carbon dioxide removal. VR correlates well with physiologic dead space fraction (VD/VT) and clinical outcomes in patients with acute respiratory distress syndrome (ARDS). We hypothesized that high VR would identify COVID-19 ARDS patients with higher risk for death and organ failure. METHOD(S): We conducted a retrospective cohort study of patients admitted to a single hospital in New York, NY, USA from March-July 2020 who had PCR-confirmed SARS-CoV-2 infection, met the Berlin criteria for ARDS, and required tracheostomy for prolonged invasive mechanical ventilation (MV). MV parameters were collected 2-8 hours after intubation. Based on prior studies, a VR>2 was considered to be abnormally elevated. Comparisons were performed using the Wilcoxon rank-sum test or z-test for difference in proportions with alpha=0.05. The primary outcome was 30- day mortality and the secondary outcome was a composite endpoint of death or organ failure defined as requiring renal replacement or extracorporeal membrane oxygenation (ECMO) during the hospitalization. RESULT(S): Of 139 subjects enrolled, 67 (48.2%) had a VR>2. Low and high VR groups had similar baseline characteristics, including age (mean 58 years, SD +/-15.2), body mass index (30.1+/-6.69 kg/m2), simplified acute physiology score II (35.4+/-12.4), sequential organ failure assessment (SOFA) score (5.7+/-2.5), and a 19-point review of systemic disease history. High VR was not significantly associated with mortality (OR 0.92, p=0.827). However, high VR was associated with increased risk for the composite endpoint (OR 1.96, p=0.049) and independently identified patients with a higher risk of organ failure (OR 2.03, p=0.047). High VR was also associated with longer hospital length-of-stay for subjects who survived to discharge (52 vs. 43, p=0.035), more MV-free days within the 30 days after intubation (3.2 vs. 1.8, p=0.029), and higher SOFA score at 10+/-4 days post-intubation (6.2 vs. 4.8, p=0.024). CONCLUSION(S): Ventilatory ratio identifies COVID-ARDS ventilated patients with increased risk for organ failure requiring advanced intervention, as well as patients who may require prolonged mechanical ventilation and hospitalization.
ABSTRACT
INTRODUCTION: Mortality and morbidity associated with COVID-19 acute respiratory distress syndrome (ARDS) has been associated with pulmonary vasculopathy, which has been hypothesized to increase pulmonary dead space (VD/ VT). However, VD/VT is rarely measured at the bedside. As a result, multiple proxy estimates have been developed. Our hypothesis was proxy estimates for VD/VT would have differing utilities in prognostication of COVID-19 ARDS. METHOD(S): We conducted a retrospective cohort study of patients admitted to an intensive care unit with SARSCoV- 2 ARDS who required invasive mechanical ventilation. Ventilation parameters were collected 2-8 hours after intubation. The VD/Vt proxies examined were 1) ventilatory ratio (VR), 2) estimation of VD/VT using the Harris-Benedict equation for energy expenditure (VD/VT-HB), 3) direct estimation of VD/VT using Beitler et. al.'s formula (VD/VTDir), and 4) corrected minute ventilation (VECorr). For each proxy, subjects were dichotomized using the median value. Comparisons were performed using the Wilcoxon rank-sum test with alpha=0.05. RESULT(S): For 139 subjects, mean VR was 2.08 (SD+/-0.80), mean VD/VT-HB was 0.614 (+/-0.15), mean VD/VT-Dir was 0.657 (+/-0.08), and mean VECorr was 12.2 (+/-4.6) L/min. All four proxies had strong inter-measure correlation (Pearson's r 0.748-0.881, p< 0.001 for all comparisons). No proxy was predictive of 30-day hospital mortality. High VR and VECorr were associated with increased morbidity using a composite endpoint of death or organ failure (defined as requiring renal dialysis or extracorporeal membrane oxygenation) with both having an odds ratio of 2.20 (95% CI: 1.12-4.33, p=0.022), while VD/VT-HB (p=0.552) and VD/VT-Dir (p=0.554) were not significantly associated. Of all proxies, only VR was significantly associated with increased sequential organ failure assessment (SOFA) score at 10+/-4 days post-intubation (6.2 vs. 4.8, p=0.024) and more ventilatorfree days within the 30 days after intubation (3.2 vs. 1.8, p=0.029). CONCLUSION(S): Ventilatory ratio and corrected minute volume appear to have stronger associations with morbidity in COVID-19 ARDS compared to other VD/VT estimates. Ventilatory ratio is also associated with ventilator-free days and delayed SOFA score.
ABSTRACT
INTRODUCTION: Ventilatory ratio (VR) is a bedside index of impaired ventilation that can be used as a surrogate marker for pulmonary dead space fraction (VD/VT). Vasculopathy is hypothesized to increase VD/VT in patients with acute respiratory distress syndrome (ARDS) due to COVID-19. The purpose of this study was to investigate associations between VR and markers of inflammation in critically ill COVID-ARDS patients. METHOD(S): We conducted a retrospective study of patients admitted to an intensive care unit due to SARS-CoV-2 infection. All subjects required invasive mechanical ventilation and met the Berlin criteria for ARDS. Clinical lab values were collected at two timepoints: 2-8 hours after intubation (T1) and 2-24 hours before tracheostomy (T2). VR was split into high (VR>2) and low (VR< 2) groups. Comparisons were performed using student's t, Mann-Whitney, and z tests for difference in proportions with alpha=0.05. RESULT(S): Of the 139 subjects enrolled at T1, 67 (48%) had high VR (>2), with an overall mean VR of 2.08. High VR was significantly associated with leukocyte count (WBC) (13.3 vs. 10.6 x10
ABSTRACT
The advancement of Artificial intelligence (AI) is found to have dual appearances as it can create the betterment of society and can threaten employment. AI is the automating process which has led to innovation in various educational methods as well as automated business procedures. Major disease areas that use AI tools include cancer, neurology and cardiology. The emergent idea of adopting AI in the drug development process has shifted from hype to hope. AI chains the decision-making processes for prevailing drugs & expanded treatments for other conditions, as well as accelerates the clinical trials procedure by finding the right patients from a number of data sources. Integrating AI into the healthcare ecosystem allows for a multitude of benefits, including automating tasks and analysing big patient data sets to deliver better healthcare faster, and at a lower cost. Machine learning, deep learning and Artificial Intelligence can be utilised to revolutionise the drug development process. At present, the main concern of the Pharmaceutical industry is drug development programmes because of increased R&D costs and reduced efficiency. In this review, we will discuss the applications and role of AI and the possible ways it can advance the effectiveness of the drug development process.
ABSTRACT
COVID-19 is a disease caused by the novel coronavirus,which was initially called 2019-nCoV, consequently termed as SARSCoV-2 by the experts of the International Committee on Taxonomy ofViruses (ICTV) as it is exceptionally alike to the virus that caused theSARS outbreak in 2002 to 2003. World Health Organization already haddeclared COVID-19 as an international emergency as the disease isspreading at alarming levels. COVID-19 has affected more than1,016,372 people around the world and killed more than 53,238 people.And even where the virus hasn't yet spread, hospitals and clinics aroundthe world have been preparing for a rush forward of coronavirus patientsas a priority over everyday illnesses they treat. The label .,internationalemergency? has triggered governments of various countries to activatevigilance plans and probably take emergency measures to protect thepublic, such as more strong travel and trade restrictions. It is beingobserved that this is the first time this kind of virus, a coronavirus, hasbeen labeled a pandemic, "but at the same time, it is being believed that itwill be able to be contained or controlled if adopted proper measures.Since information about this virus is rapidly rising, it is the necessity ofthe time to remain updated. So in this article, we present on an overviewof the presently obtainable information on the etiology, pathophysiology,epidemiology, clinical manifestations and diagnosis, therapeuticstrategies, and management of this novel coronavirus. This review alsoaimed to present the concept of epidemic and pandemic phases accordingto WHO in a defined manner. Copyright © 2013 are reserved by the International Journal of Pharmaceutical Sciences and Research.